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LONG-TERM RESULTS OF PANCREAS TRANSPLANTATION 
UNDER TACROLIMUS IMMUNOSUPPRESSION1 
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Background. The long·term safety and efficacy of ta-
crolimus in pancreas transplantation has not yet been 
demonstrated. The observation of prolonged pancreatic 
graft function under tacrolimus would indicate that any 
potential islet toxicity is short-lived and clinically insig. 
nificant. We report herein the results of pancreas trans-
plantation in patients receiving primary tacrolimus im· 
munosuppression for a minimum of 2 years. 
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Methods. From July 4, 1994 until April 18, 1996, 60 
patients received. either simultaneous pancreas-kid. 
ney transplant (n=55), pancreas transplant only (n=4), 
or pancreas after kidney transplantation (n=l). Base-
line immunosuppression consisted of tacrolimus and 
steroids without antilymphocyte induction. Azathio. 
prine was used. as a third agent in 51 patients and 
mycophenolate mofetil in 9. Rejection episodes within 
the first 6 months occurred in 48 (80%) patients and 
were treated with high-dose corticosteroids. Antilym. 
phocyte antibody was required in eight (13%) patients 
with steroid·resistant rejection. 
Results. With a mean follow-up of 35.1±5.9 months 
(range: 24.3-45.7 months), 6·month and 1·,2-, and 33· 
year graft survival is 88%, 82%, 80%, and 800/" (pan· 
creas) and 98%, 96%, 93%, and 91% (kidney), respec· 
tively. Six·month and 1·,2-, and 3-year patient survival 
is 100%,98%,98%, and 96.5%_ Mean fasting glucose is 
91.6±13.8 mg/dl. and mean glycosylated hemoglobin is 
5.1±0.7% (normal range: 4.3-6.1%). Mean tacrolimus 
dose is 6.5±2.6 mglday and mean prednisone dose 
2.0±2.9 mg/day at follow.up. Complete steroid with-
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drawal was possible in 31 (65%) of the 48 patients with 
functioning pancreases. 
Conclusions. These data show for the first time that 
tacrolimus is a safe and effective long·term primary 
agent in pancreas transplantation and provides excel-
lent long-term islet function without evidence of tox-
icity while permitting steroid withdrawal in the ma-
jority of patients. 
Simultaneous pancreas-kidney (SPK*) transplantation 
has enjoyed increasing success over the last decade and has 
therefore become accepted therapy for diabetic patients with 
end-stage renal disease. However, with both SPK, and even 
more so with pancreas transplantation alone (PTA) and pan-
creas after kidney transplantation (P AK), success is limited 
by rejection rates with cyclosporine (CsA)-based therapy re-
ported as high as 60-80%, even when induction antilympho-
cyte therapy has been used (1-3). The introduction oftacroli-
mus (TAC) has ushered in a new era for immunosuppression 
of solid organ recipients. Its use is associated with a lower 
incidence of acute rejection in primary kidney transplanta-
tion compared with CsA in both U.S. and European multi-
center trials (4, 5). TAC also has the ability to rescue kidney, 
liver, and pancreas grafts from rejection refractory to stan-
dard immunosuppressive protocols (6-8) and has the added 
advantage of permitting concomitant steroid tapering in both 
adult (9) and pediatric (10) renal transplantation, with up to 
60% of patients eventually weaned from prednisone. Addi-
tional data suggest that TAC may also yield longer half-lives 
for kidney transplants than standard CsA-based regimens 
(11). These observations have encouraged several centers, (8, 
12, 13) including our own (14), to evaluate the safety and 
efficacy of TAC as primary therapy for pancreas transplan-
tation. Thus far, reports with relatively short-term (one year 
or less) follow-up have confirmed the utility of TAC, and in 
some cases, suggested it is superior to CsA for SPK (8, 12, 
14). Because of the reported potential for diabetogenicity 
associated with TAC (4-6, 9, 15), there has been reluctance 
by some centers to adopt this drug for primary pancreas 
transplantation, even though the reputed diabetogenicity 
has been shown to be short-lived and reversible in the ma-
jority of cases (4-6, 9, 10, 15). Nevertheless. we felt it impor-
tant to examine in more detail the outcome of pancreas 
transplantation under TAC, especially in the long term, pay-
ing particular attention to the long-term diabetogenic poten-
tial, which has utmost relevance in the pancreas transplant 
recipient. We. therefore, report herein our experience in the 
first 60 pancreas recipients transplanted at our institution 
under TAC immunosuppression, all of whom have been fol-
lowed for a minimum of 2 years. The results support the use 
of TAC as a safe long-term agent for pancreas transplanta-
tion without an increased risk of posttransplant diabetes 
compared with traditional CsA-based regimens. 
PATIENTS AND METHODS 
Donor and recipient demographics. Between July 4, 1994 and 
April 18, 1996, 60 patients (29 men, 31 women) with a mean age of 
* Abbreviations: AZA. azathioprine: CIT. cold ischemia time: 
CMV. cytomegalovirus; CsA cyclosporine A; HbgA1e , glycosylated 
hemoglobin: MMF. mycophenolate mofetil: PAK. pancreas after kid-
ney; PTA. pancreas transplant alone: PTDM, posttransplant diabe-
tes mellitus: SCr, serum creatinine: SPK. simultaneous pancreas-
kidney; TAC, tacrolimus. 
36.8 := 6.3 years (range: 25.8-52.6 years) received TAC-based im-
munosuppression as primary therapy for cadaver pancreas trans-
plantation. Fifty-five (92%) patients underwent simultaneous pan-
creas-kidney (SPK) transplantation, 4 (6.5%) a pancreas transplant 
alone (PTA), and 1 (1.5%) a pancreas after a previous kidney trans-
plant (PAlO. Of the 55 SPK patients, 49 (89%) were primary kidney 
transplant recipients and 6 (11%) were undergoing repeat transplan-
tation (5 second, 1 third). All patients were undergoing primary 
pancreas transplantation. The mean number of HLA matches and 
mismatches was 1.4:=1.1 and 4.3:=1.2, respectively (Table 1). The 
mean donor age was 26.2:=12.9 years (range: 6-54 years). Eight 
donors were ~4R years old, and 14 were :5 15 years old. The mean 
cold ischemia time (CIT) for the kidney transplants was 14.9:=5.2 hr 
(range: 6-25 hr) and for the pancreas transplants 16.8:=4.9 hr 
(range: 7-28 hr). Seventeen of the pancreas transplants were 
drained into the bladder, and 43 were drained entericaliy. 
Immunosuppresswn. All patients received primary TAC-based 
immunosuppression with a steroid tapering regimen, as described 
previously (14). Antilymphocyte antibody induction was not used. In 
addition to TAC and steroids, 51 (85%) patients received azathio-
prine (AZA) at 2 mglkg/day and 9 (15%) received mycophenolate 
mofetil (MMF) (CellCeptR ) at 1 g twice daily. AZA and MMF doses 
were titered to maintain a white blood cell count >5000/mm3 and 
according to gastrointestinal side effects in the case of MMF. Pa-
tients received intravenous TAC at 0.05 mglkg/day for 5 days post-
operatively, followed by an initial oral dose of 0.15 mglkg twice daily. 
The TAC dose was adjusted to achieve target whole blood trough 
levels of 20-25 ng/ml in the first 2 weeks after transplant, 15-20 
ng/ml by 1 month, 10-15 ng/ml by 2 months, 7-12 ng/ml by 6 
months, and 5-10 ng/ml thereafter. In the presence of stable graft 
function steroids were tapered by 2.5-5 mg every 2 weeks with the 
aim of complete steroid weaning by 12-18 months. All patients 
received prophylaxis for Pneumocystis carinii pneumonia with tri-
methoprim-sulfamethoxazole. Cytomegalovirus (CMVl-seronegative 
recipients of CMV-seropositive organ donors (n=14) had biweekly 
testing for CMV antigen (pp65) and were treated with a 14-day 
course of intravenous ganciclovir if CMV antigenemia was positive. 
Routine prophylaxis for CMV was not given. 
Rejection. The diagnosis of acute rejection was suspected in pa-
tients with a > 10% increase in baseline serum creatinine (SCr) or a 
rising or sustained increase in serum lipase (15), or both. The pres-
ence of rejection was confirmed either by fine needle aspiration 
biopsy of the kidney or pancreas or core needle biopsy of the kidney, 
or both. Biopsy-confirmed rejection was treated with either intrave-
nous solumedrol boluses (generally 500 mg daily for 3 days) or by a 
tapering steroid recycle (200 mg to 20 mg over 6 days). Steroid-
resistant rejection episodes were treated with antilymphocyte anti-
body (OKT3 or ATGAM) for 7-14 days. 
Statistical analysis. Patient survival rate was calculated from the 
date of transplantation until death, and the graft (kidney or pan-
creas) survival rate from the date of transplantation until graft 
failure or patient death. Survival curves were generated using the 
Kaplan-Meier (product limit) method. Data were analyzed for statis-
tical significance by analysis of variance where appropriate. 
TABLE 1. HLA matches and mismatches 
No. QfHLA No. of patients No.ofHLA No. of patients 
matches (%) mismatches (%) 
0 15 (25%) 0 0(0%) 
1 22 (37%) 1 2(3%) 
2 12 (20%) 2 4(7%) 
3 9 <15%) 3 8 (13%) 
4 2 (3%) 4 16 (27%) 
5 0<0%) 5 23 (38%) 
6 0(0%) 6 7 (12%) 
I 
I 
I ; 
, 
1-
-- ----------------------------------
268 TRANSPLANTATION Vol. 67, No.2 
RESULTS 
Patient and graft survival. The mean follow-up was 
35.1:t5.9 months (range: 24.3-45.7 months). Overall 
6-month and 1-, 2-, and 3-year actuarial patient survival was 
100%, 98%, 98%, and 96.5% (Fig. 1). Of 60 recipients, 57 
(95%) are currently alive. One PTA patient died of a brain 
stem infarct 10 months after transplant; this patient had lost 
her graft at 3 months to recurrent rejection. The two other 
deaths occurred in SPK patients. One patient died of multi-
ple system organ failure and inanition 25 months after trans-
plant with a functioning kidney graft; this patient had lost 
the pancreas to severe pancreatitis 13 days after transplant. 
A second SPK patient died 39 months after transplant of 
unknown causes on dialysis; the lymphocytotoxic cross-
match had become positive on the third day after transplant 
and she subsequently lost her kidney and pancreas at 12 and 
21 days after transplant, respectively, owing to antibody-
mediated rejection. 
Overall 6-month and 1-,2-, and 3-year actuarial pancreas 
graft survival was 88%, 82%, 80% and 80%, and kidney graft 
surviva198%, 96%, 93%, and 91% (Fig. 2). Of the 60 pancreas 
grafts, 48 (80%) are currently functioning. The 12 pancreas 
graft losses occurred in 12 (20%) patients-10 of the 55 SPK 
patients and 2 of the 4 PTA patients. 
Cumulative pancreas graft loss from rejection was 3% at 6 
months, 6.5% at 1 year, and 8% at 2 and 3 years. Of 56 kidney 
grafts, 49 (88%) are currently functioning. Cumulative kid-
ney graft loss from rejection was 3.5% at 6 months, 3.5% at 1 
year, 7% at 2 years, and 9% at 3 years. The causes of pan-
creas and kidney graft loss are shown in Table 2. Overall, 12 
pancreases were lost; 9 within 22 days after transplantation 
and 1 each at 2.5 months, 8.8 months, and 20 months after 
transplant. Four pancreases were lost to rejection, three to 
thrombosis, two to infection (one Candida, one splenic artery 
anastomotic pseudoaneurysm with abscess), two as a result 
of severe pancreatitis, and one to duodenal ischemia with 
fistula. High-risk donor factors contributing to the eight non-
immunologic graft losses could be identified in five cases and 
included prolonged CIT (23 hr) and pressor support in one, a 
ligated inferior pancreaticoduodenal artery that was unrec-
ognized at the time of organ recovery in one, donor obesity 
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FIGURE 1. Kaplan Meier patient survival of 60 patients receiving 
SPK (n=55). PAK (n=4). or PTA (n=ll. Numbers in parentheses 
indicate patients at risk at each time point. 
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FIGURE 2. Kaplan Meier kidney (-. n=56) and pancreas (- - - , 
n=60) graft survival. Numbers in parentheses indicate grafts at risk 
at each time point. 
(weight 127 kg) in one, donor hypernatremia (N a = 170 
mEqlL) in one, and donor pneumococcal sepsis with a hem-
orrhagic capillary leak syndrome in one. Renal graft losses 
were caused by rejection in six cases and patient death in one 
case. 
Rejection. Biopsy-proven rejection episodes within the 
first 6 months after transplantation occurred in 48 of 60 
(80%) patients, including 43 of 55 SPK (78%), 4 of 4 PTA 
(100%), and the 1 PAK patient. Rejection episodes were clas-
sified as mild (Banff grade 1) in 33 (69%) patients, moderate 
(Banff grade II) in 13 (27%), and severe (Banff grade III) in 2 
(4%). Acute rejection was treated with high-dose corticoste-
roids and optimization of TAC levels initially in all cases, 
with reversal in 40 of 48 (83%). Of the 48 patients with 
rejection, 8 (17%) did not respond to high-dose steroids and 
were treated with a 7-14-day course of antilymphocyte anti-
body (OKT3 in 6, ATGAM in 2) with reversal of rejection in 7 
(88%). In 2 of the 60 patients, the rejection episodes were 
irreversible and progressed to kidney graft loss at 12 and 32 
days and pancreas graft loss at 21 and 14 days after trans-
plant, respectively. One of these patients had developed a 
positive lymphocytotoxic cross-match after transplant, as de-
scribed above. 
Long-term immunosuppression and outcome. All patients 
received TAC for primary immunosuppression. Two patients 
(one SPK, on PTA) were converted to Neora! at 6 and 19 
months after transplant, respectively, in unsuccessful at-
tempts to reverse ongoing rejection; both patients lost their 
pancreas grafts, at 8.8 months and 20 months after trans-
plant. respectively, to chronic rejection. The SPK patient 
continues to have a functioning renal transplant (SCr= 1.8 
mg/dll at 34 months after transplant. An additional patient 
who had two rejection episodes was switched to Neoral 12 
months after transplant for persistent hyperglycemia (glu-
cose> 180 mg/dl) but continues to have elevated glucose lev-
els. 
Of the nine patients originally on TAC-MMF, two (one 
PTA, one SPK) have lost their grafts (pancreas and kidney, 
respectively) to rejection. Four of the nine TAC-MMF pa-
tients were taken ofT MMF; three were switched to AZA 
• ! 
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Graft type Patient Date of transplant 
TABLE 2. Causes of graft loss 
~~--~--~-----------------­Cause of graft loss (time after transplant) 
Pancreas Kidney 
SPK RC 
SPK DB 
9/19/94 
9/28/94 
Antibody-mediated rejection (21 days) 
Thrombosis (1 day) 
Antibody-mediated rejection (12 days) 
Normal function \44 months) 
SPK TS 1117194 
SPK AB 11126194 
Ischemia of duodenum with fistulaa (5 days) 
Candida infection (14 days) 
Chronic rejection (38.5 months) 
Acute rejection (32 days)b 
SPK TM 1217194 Low-flow necrosis (10 days) Normal function (40.5 months) 
Normal function (39 months) SPK JM 1118195 Thrombosis (1 day) 
SPK DP 
SPK JG 
1121195 
5127/95 
Normal islet function (39 months) 
Recurrent rejection (20 months) 
Chronic rejection (35.7 months) 
Normal function (35 months) 
SPK CM 7/10/95 Splenic artery anastomotic pseudoaneurysm, Chronic rejection (14.2 months) 
abscess (22 days) 
SPK TM 
SPK KS 
8119/95 
10/21195 
Necrotizing pancreatitis (1 day) 
Thrombosis (1 day) 
Death with graft function (24.6 months) 
Normal function (30 months) 
SPK JO 
PTA DY 
2116196 
7127/95 
Normal islet function (26 months) 
Rejection (2.5 months) 
Chronic rejection <17.3 months) 
NAc 
PTA DB 9/17/95 Rejection (8.8 months) 
a Ligated inferior pancreaticoduodenal artery. 
b Immunosuppression stopped at 14 days. 
C NA, not applicable. 
NA 
TABLE 3. Graft function and metabolic parameters in pancreas-kidney patients receiving TAca 
Time after transplant SCr Fasting TAC trough TAC dose glucose level (mo) (mg/dl) (mg/dD (ng/mD (mg/day) 
1 1.8:t 1.5 90.8:t15.0 15.4:tS.1 19.5:t7.7 
3 1.4:t0.5 9S.7:t20.0 12.8:t4.9 13.0:t5.9 
S 1.4:t0.S 89.8:t14.8 1O.1:t3.1 9.5:!:3.8 
12 1.4:t0.6 93.9:t20A 10.0:t2.9 7.4:t2.S 
24 1.4:!:0.8 93.7:t 18.1 8.4:t2.7 6.3:t2.1 
At follow-upb 1.5:t0.9 92.0:t20.7 8.0:t2.0 6.2:t1.8 
P(ANOVAJ< 0.035 
a SPK patients with functioning grafts. 
b Mean follow-up: 32.5:t6.3 mo. 
C Analysis of variance with repeated measures. 
because of gastrointestinal side effects resistant to MMF dose 
reduction, and one PTA patient was switched to Cytoxan and 
Neoral in an unsuccessful attempt to reverse ongoing rejec-
tion. Of the 51 patients originally receiving TAC-azathio-
prine (TAC-AZA), eight were converted to TAC-MMF be-
cause of rejection; of these, one SPK patient lost her kidney 
transplant to chronic rejection at 35.7 months but continues 
to have pancreas graft function, and one lost his pancreas to 
rejection at 20 months but continues to have renal graft 
function. Overall. of the 51 patients originally on TAC-AZA. 
pancreas graft loss occurred in 11 patients and kidney graft 
loss in 6. Of the 48 patients with functioning pancreases, 31 
(65%) have been weaned off prednisone at a mean of 
17.0:t9.9 months (range: 8-39 months) after transplant; 2 
are taking 10 mg/day; 3 are taking 7.5 mg/day, 10 are on 5 
mg/day, 1 is taking 5 mg and 2.5 mg on alternate days, and 
1 is on 2.5 mg/day. One SPK patient had initially been 
weaned off prednisone 11 months after transplantation but 
experienced a late mild rejection episode at 14 months. 
treated successfully with high-dose steroids. This patient 
currently has good renal and pancreatic graft function 
(SCr= 1.8 mgldl. fasting glucose=81 mg/dll and is on 10 mg of 
prednisone daily, in addition to 8 mg of T AC and 500 mg of 
MMF daily. No other patients weaned ofT steroids has sub-
0.49 <0.001 <0.001 
sequently had a rejection episode or has been restarted on 
steroids. Of the 49 patients with functioning kidneys (48 
SPK, 1 PAK), the mean prednisone dose is 2.2::3.2 mg/day; 
32 (65%) are currently off prednisone and 3 are taking 10 
mg/day, 3 7.5 mg/day, 10 5 mg/day, and 1 is taking 5 and 2.5 
mg on alternate days. 
Graft function and TAC. Of the 48 patients with a func-
tioning pancreas (45 SPK, 2 PTA. 1 PAK), 47 remain on TAC 
and 1 has been switched to Neoral because of persistent 
hyperglycemia (fasting glucose> 180 mg/dl); this latter pa-
tient currently has a fasting glucose ranging from 130 to 170 
mg/dl on Neoral at 150 mg twice daily, 5 mg of prednisone, 
and at MMF 500 mg twice daily. In the other 47 patients. the 
mean TAC dose is 6.3:: 1.8 mg/day and the mean TAC level is 
8.0::2.2 ng/ml. Corresponding mean fasting glucose levels in 
these 47 patients are 91.6=13.8 mg/dl. and mean glycosy-
lated hemoglobin (HbgA1C ) is 5.1:!:O.7% (normal range: 4.3-
6.1%), Fasting glucose. SCr. TAC dose. and TAC levels at 
corresponding time points after transplantation in the 45 
SPK patients with functioning grafts are shown in Table 3. In 
the two patients with functioning grafts after PTA. mean 
fasting glucose is 99.5=21.9 mg/dl with a mean TAC level of 
11.5 ng/ml (TAC dose of 6.0:t2.8 mg/day) at a mean of 31.1 
months' follow-up; in the PAK patient. fasting glucose is 69 
r 
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mg/dl and SCr is 1.2 mg/dl with a trough TAC level of 6.5 
ng/ml on a TAC dose on 5 mg of TAC/day at 30 months' 
follow-up. 
Transient hyperglycemic episodes. Transient hyperglyce-
mic episodes (defined as a rise in blood glucose over 180 
mg/dl) occurred in a total of 26 patients at a mean of 
45.2:t118 days after transplant (median: 23 days). These 
episodes were associated with treatment of rejection in 16 
(62%) of26 cases and TAC toxicity in 1 (4%). Nine patients in 
whom the cause of hyperglycemia was unknown were evalu-
ated to search for possible donor-related causes that could 
account for delayed graft function. The mean donor age for 
these patients was 29:t 14.8 years (median: 35 years). The 
mean CIT was 17.5:t4.9 hr (median: 18 hr). Seven of nine 
(78%) ofthese donors were on pressors before organ retrieval 
(four were on >2 pressors). In the other two cases, no obvious 
cause for the transient hyperglycemic episode could be dis-
covered. During transient hyperglycemic episodes, mean 
blood glucose level was 218:t82 mg/dl (median: 200 mg/dI). 
The mean TAC level during episodes of hyperglycemia was 
19.2:t9.1 ng/ml (median: 17.6 ng/mD with a concomitant 
mean oral TAC dose of 18.5:t6.7 mg/day (median: 18 mg/ 
day). In the 16 cases where hyperglycemia was associated 
with treatment of rejection, intravenous TAC was used to 
optimize trough TAC levels in 3 patients at a mean dose of 
1.5:t0.76 mg/day. Bolus therapy with solumedrol was given 
in all 16 patients to treat rejection. Mean SCr during hyper-
glycemic episodes was 2.0:t1.2 mg/dl. In none of these pa-
tients did the transient hyperglycemic episode result in graft 
loss or diminished long-term pancreatic function, and all 
have normal glucose metabolism beyond 2 years. 
DISCUSSION 
Tacrolimus has gained widespread acceptance as an effec-
tive immunosuppressive agent in solid organ transplantation 
as both a primary (4, 5, 7-10) and rescue agent (6, 7,8, 17). 
In randomized trials of TAC and CsA for renal transplanta-
tion, short-term outcomes have shown that TAC is superior 
to CsA in reducing rejection incidence (4, 5), and possible 
long-term advantages for renal allograft half-life have also 
been described (11). An additional advantage of this drug, 
demonstrated in our own institution, is its steroid-sparing 
effects, with complete steroid withdrawal possible in up to 
60% of renal allograft recipients (9, 10). Accompanying these 
favorable observations have been concerns over the diabeto-
genicity of TAC, which has been reported in the short term 
with an incidence ranging from 6% to 28% of renal transplant 
patients (4, 5, 9, 10, 16). However, the final incidence of 
posttransplant diabetes mellitus (PTDM) in these studies 
ranges from 1.4% to 12.6%, which is no different than that in 
CsA-based regimens, and is reversible in 37-83% (4, 5, 9, 10, 
16). In our experience, this reversibility can be maximized 
with judicious early (over 2-3 months) TAC dose reduction, 
along with steroid tapering. 
Potential reasons for impaired glucose metabolism and 
transient hyperglycemia in the early postoperative period 
after pancreas transplantation include impaired early insu-
lin secretion by the recovering ischemic graft, reduced l3-cell 
responsiveness, impaired nonoxidative glucose metabolism. 
and impaired early inhibition of glucagon secretion (8). The 
diabetogenic effects of TAC in rats have been shown to in-
volve transcriptional inhibition of insulin mRNA caused by 
the binding of TAC to FKBP-12, which is present in high 
concentration in pancreatic B cells, with subsequent inhibi-
tion of calcineurin activity in these cells (19). However, when 
TAC administration (which was given at a higher than ther-
apeutic dose of 10 mg/kg/day in this study) was stopped, 
insulin mRNA transcription and insulin production normal-
ized (19). Other experimental studies have confirmed that 
TAC's effects on in vitro inhibition of insulin gene transcrip-
tion are reversible and are time- and dose-dependent (20). In 
fact, one study even showed that TAC protects mouse pan-
creatic islets from streptozocin-induced injury (21). Further-
more, in a randomized trial comparing CsA and TAC in liver 
transplant recipients, Steinmuller and colleagues (22) found 
no differences in the incidence of impaired glucose tolerance 
or clinically significant PTDM. Strumph reported that the 
oral glucose tolerance test and HgbA1c levels were un-
changed in seven nondiabetic autoimmune subjects after 10 
weeks of FK 506 therapy (23). These experimental and clin-
ical observations recapitulate observations made by our-
selves (9,10) and others (4, 5) demonstrating the reversibility 
of TAC-induced PTDM. 
Despite these observations, justifiable concern has been 
expressed over the use of a potentially (albeit reversible) 
diabetogenic agent such as TAC for pancreas transplanta-
tion. The short-term safety and efficacy of TAC in pancreas 
transplantation has been reported in both single-center and 
multicenter trials for both primary and rescue therapy (8, 
12-14). Gruessner has recently shown in a follow-up multi-
center analysis of TAC immunosuppression for pancreas al-
lograft recipients statistically significant improvements in 
I-year graft survival of SPK patients when compared to a 
matched pair group receiving CsA (12). In his study, only 4% 
of recipients were converted from TAC to CsA for diabetoge-
nicity by 1 year. However, no details on TAC dosing and 
levels or steroid dose were provided for these patients (12). Of 
note, 86% of the recipients in the retrospective multicenter 
analysis by Gruessner had received anti-T-cell induction 
therapy along with TAC, steroids, and either azathioprine 
(94%) or MMF (5%), and steroid tapering was not mentioned. 
Other studies (13,24-26) have also reported the use ofTAC 
for pancreas transplantation in small numbers of patients 
with short-term follow-up, but its safety and efficacy in the 
long term, particularly with respect to the potential for sus-
tained graft function without clinical evidence of islet toxic-
ity, has not been reported. Therefore, we thought it prudent 
to analyze our experience with TAC for primary pancreas 
transplantation in patients with a minimum of 2 years' fol-
low-up. 
In the current study, 60 patients receiving pancreas trans-
plants between July 4, 1994 and April 18, 1996 have been 
followed for a mean of 35.1 months. The majority (85%) 
received TAC-AZA with prednisone. During the latter part of 
this early experience with TAC-based immunosuppression, 
MMF was used instead of AZA as a third drug in nine 
patients. Although our rejection incidence of 80% is some-
what higher than that reported in other recent studies with 
TAC-based therapy for pancreas transplantation (2), the 
majority (69%) of these rejections were classified as mild and 
none of these patients had received anti-T-cell induction 
therapy. Furthermore, only eight patients (17%) required 
OKT3 for steroid-resistant rejection. Steroid withdrawal was 
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accomplished in 65% of the patients at a mean of 17.0:±:9.9 
months after transplantation. Prednisone was reinstituted 
after its discontinuation in only one patient who experienced 
a late mild rejection episode 1 year after transplantation. The 
number of patients receiving MMF was too small to draw any 
meaningful conclusions regarding its potential benefits as a 
third agent with TAC-prednisone, although in a larger pa-
tient group with shorter follow-up at our institution, MMF 
appears to confer an immunologic benefit with a lower inci-
dence of rejection (27). MMF has been subsequently incorpo-
rated as part of our routine immunosuppressive regimen for 
pancreas transplantation. 
The efficacy ofTAC-based immunosuppression without the 
use of induction antilymphocyte antibody, in both kidney (9, 
10), and now pancreas transplantation (14), is perhaps best 
reflected by the current series, in which long-term graft func-
tion without evidence of islet toxicity, reflected by mean 
fasting glucose levels of 90.4:±: 17.6 mg/dl (range: 43-135) and 
HgbA1C of 5.1:±:O.7% (range: 3.2-6.5%), was observed at a 
mean follow-up of 35.1:±:5.9 months. In the group of patients 
exhibiting transient hyperglycemia, the mean TAC level of 
19.2:±:9.1 and the mean oral TAC dose of 18.5:±:6.7 mg/day 
were quite high. Dose reduction resulted in resolution of 
hyperglycemia in all cases, confirming that the hyperglyce-
mia in these patients was TAC dose-dependent. Further-
more, the glucose remained normal beyond 2 years. 
Our center has now performed 147 pancreas transplants 
under TAC-based immunosuppression. In the initial group of 
60 patients reported herein, long-term pancreatic graft func-
tion without evidence of islet toxicity along with the ability to 
taper steroids in 65% of patients, accompanied by a very low 
incidence <13%) of steroid-resistant rejection requiring anti-
lymphocyte antibody treatment, have reassured us that TAC 
is both safe and effective for long-term outcome in cadaver 
pancreas transplantation. 
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CHRONIC vmAL HEPATITIS IN RENAL TRANSPLANT 
RECIPIENTS WITH ALLOGRAFTS FUNCTIONING FOR MORE 
THAN 20 YEARS1,2 
ZOBAIR M. YOUNOSSI,3.4 WILLIAM E. BRAUN,5 DEBORAH A. PROTIVA,5 
RAy W. GIFFORD, JR.,5 AND RALPH A. STRAFFON6 
Department of Gastroenterology, Department of Nephrology and Hypertension, and Department of Urology, 
Cleveland Clinic Foundation, Cleveland, Ohio 
Background,. The impact of infection with hepato-
tropic viruses (hepatitis B virus [HBV] and hepatitis C 
virus [HeV]) on morbidity and mortality, and allograft 
function in renal transplant recipients with allografts 
functioning for >20 years is not known. 
Methods and Result.. Seventy-nine of 511 renal 
transplants performed at the Cleveland Clinic Foun-
dation from January 1963 to January 1978 are known 
to have functioned for at least 20 years (level 5A). 
Fifty-four of these patients had hepatitis testing up-
dated after their 19th year of transplantation. Fifteen 
patients had evidence of ongoing viral infection: per-
sistent hepatitis B surface antigen in three (6%), Hev 
antibody (enzyme-linked immunosorbent assay II sup-
plemented by recombinant immunoblot assay) in 11 
(20%), and both viruses in one (2%). Ofthe 10 surviving 
patients, 8 were tested further for viral replication. 
Hev RNA (polymerase chain reaction; Amplicore) was 
positive in 617 (86%), and HBV DNA (hybridization) 
was positive in 112 (50%). An elevated alanine amino-
transferase (>35 UIL) was present in all hepatitis pa-
tients, a-fetoprotein > 10 npl in 218 (25%), and cryo-
globulins >50 "gIml in 3/6 (50%) infected with Hev. No 
hepatocellular carcinoma was detected by hepatic ul-
trasound. In patients with chronic viral hepatitis, 
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American Society of Transplant Physicians. May 9-13. 1998. Chi-
cago.IL. 
2 This work was supported by the Kidney Fund of Holmes County, 
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younossi@Cestmtp.ccf.org. 
.; Department of Nephrology and Hypertension. 
6 Department of Urology. 
probable cirrhosis developed in 20% (3115) compared 
to one patient in the group without hepatitis, but 
there was no mortality from liver failure in either 
group. Diabetes mellitus was significantly more com-
mon in those with than without hepatitis (11115 vs. 
10139; P=0.OO2), but severe infection was not (9/15 vs. 
15139). Five hepatitis patients (33%) have died of non-
hepatic causes (one from meningitis, one from un-
known cause, and three from coronary heart disease 
[CIID] vs. only two individuals without hepatitis [5%]; 
P= 0.014). Although the more frequent occurrence of 
CIID among those with hepatitis was not significant 
(7/15 vs. 8139; P=0.09), CIID as a cause of death in those 
with Hev was significantly increased (P=0.03). 
Conclusions. Twenty-year renal transplant recipi-
ents infected with hepatotropic viruses (HBV and 
HCV) have a high rate of active viral replication (88%), 
a greater frequency of diabetes (P=O.Ol), and a higher 
overall mortality (P=0.014). 
Chronic infection with hepatitis B and C viruses (HBV* 
and HCV) are relatively common in patients receiving hemo-
dialysis and in recipients of renal transplants. Chronic hep-
atitis B (hepatitis B surface antigen positivity) affects 3-10% 
of patients receiving chronic hemodialysis (1). Positive anti-
HCV serology (second-generation enzyme-linked immunosor-
bent assay assay) can be detected in 8.1% (range: 0-51%) of 
patients in selected hemodialysis units in the United States. 
but its prevalence varies considerably in different regions of 
the world (2. 3). Anti-HCV positivity has been reported in 
10-26% of renal transplant recipients, the majority of whom 
have detectable HeV RNA, as measured by the polymerase 
chain reaction method (2,3). 
* Abbreviations: CHD. coronary heart disease; HBsAg. hepatitis B 
surface antigen: HBV. hepatitis B virus: HCV. hepatitis C virus. 
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